Your session is about to expire
← Back to Search
Risk Awareness Training for Alcoholism
N/A
Recruiting
Led By Mark Fillmore, PhD
Research Sponsored by Mark Fillmore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to follow up [monthly], up to 3 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if a special type of training can help people who have been caught driving under the influence of alcohol to better understand the risks associated with drinking.
Who is the study for?
This trial is for individuals who drive on a weekly basis and have had a valid driver's license for at least five years. It specifically targets DUI offenders to help them understand the risks of alcohol use. Pregnant or breastfeeding individuals, those with substance use disorders (excluding nicotine or caffeine), or with physical or psychiatric diseases cannot participate.
What is being tested?
The study is testing two types of training: performance feedback training and blood alcohol concentration discrimination training. The goal is to see if these methods can improve DUI offenders' awareness of the risks associated with drinking and driving.
What are the potential side effects?
Since this trial involves educational interventions rather than medical treatments, traditional side effects are not applicable. However, participants may experience stress or discomfort when confronting their behaviors related to alcohol consumption.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to follow up [monthly], up to 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to follow up [monthly], up to 3 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in alcohol consumption
Change in subjects perceive improvement in their interoceptive ability
Change in tonic alcohol cravings
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Intoxicated risk awareness training sessionExperimental Treatment2 Interventions
Participants will complete an intoxicated risk awareness training session in which they receive a controlled alcohol dose with structured feedback and training to accurately appraise the impairing effects of alcohol and estimate their blood alcohol concentration (BAC).
Group II: Alcohol exposure onlyActive Control1 Intervention
Participants assigned to the alcohol-exposure-only condition undergo the same alcohol dose exposures over the session but receive a general body scan and do not receive feedback concerning BAC or performance.
Find a Location
Who is running the clinical trial?
Mark FillmoreLead Sponsor
2 Previous Clinical Trials
128 Total Patients Enrolled
1 Trials studying Alcoholism
28 Patients Enrolled for Alcoholism
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
835 Previous Clinical Trials
1,082,650 Total Patients Enrolled
457 Trials studying Alcoholism
823,786 Patients Enrolled for Alcoholism
Mark Fillmore, PhDPrincipal InvestigatorUniversity of Kentucky
1 Previous Clinical Trials
100 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had a valid driver's license for at least 5 years.I have a history of physical or mental health conditions.I drive on a weekly basis.
Research Study Groups:
This trial has the following groups:- Group 1: Alcohol exposure only
- Group 2: Intoxicated risk awareness training session
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger